EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes

Journal of Hepatology

Volumn 65, Issue 5, 2016, Pages 888-898

  Mani, Saravana Kumar Kailasam ^a,b   Zhang, Hao ^a,b   Diab, Ahmed ^a,b   Pascuzzi, Pete E ^b,c   Lefrançois, Lydie ^d   Fares, Nadim ^d   Bancel, Brigitte ^d   Merle, Philippe ^d   Andrisani, Ourania ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b Purdue University   (United States)

^c PURDUE UNIVERSITY   (United States)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

BAMBI; CD133; CD44; EpCAM regulated intramembrane proteolysis; Hepatitis B virus; Hepatocellular carcinoma; Pluripotency genes (NANOG, OCT4 and SOX2); SUZ12 polycomb repressive complex 2; Wnt signaling

Indexed keywords

BETA CATENIN; CD133 ANTIGEN; CISPLATIN; DNA METHYLTRANSFERASE 3A; EPITHELIAL CELL ADHESION MOLECULE; GREEN FLUORESCENT PROTEIN; HERMES ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN P53; SORAFENIB; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL PROLIFERATION; CELL VIABILITY; CHRONIC HEPATITIS B; CONTROLLED STUDY; HEPATITIS B VIRUS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER FIBROSIS; LIVER PARENCHYMA; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; REGULATED INTRAMEMBRANE PROTEOLYSIS; TUMOR INVASION; TUMOR VOLUME; VIRUS REPLICATION; WNT SIGNALING PATHWAY; ANIMAL; HEPATITIS B; LIVER CELL CARCINOMA; LIVER TUMOR;

ANIMALS; CARCINOMA, HEPATOCELLULAR; EPITHELIAL CELL ADHESION MOLECULE; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASTIC STEM CELLS; PROTEOLYSIS;

EID: 84995467583     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.022     Document Type: Article

References (51)

1. [1] Beasley, R.P., Hwang, L.Y., Lin, C.C., Chien, C.S., Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2 (1981), 1129–1133.
2. [2] El-Serag, H.B., Rudolph, K.L., Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007), 2557–2576.
3. [3] Colombo, M., Iavarone, M., Role of antiviral treatment for HCC prevention. Best Pract Res Clin Gastroenterol 28 (2014), 771–781.
4. [4] Zoulim, F., Locarnini, S., Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137 (2009), 1593–1608, e1591–e1592.
5. [5] Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
6. [6] Xie, B., Wang, D.H., Spechler, S.J., Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci 57 (2012), 1122–1129.
7. [7] Mishra, L., Banker, T., Murray, J., Byers, S., Thenappan, A., He, A.R., et al. Liver stem cells and hepatocellular carcinoma. Hepatology 49 (2009), 318–329.
8. [8] Fernando, J., Malfettone, A., Cepeda, E.B., Vilarrasa-Blasi, R., Bertran, E., Raimondi, G., et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer 136 (2015), E161–E172.
9. [9] Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang, W., Wang, H.Y., et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136 (2009), 1012–1024.
10. [10] Ma, S., Chan, K.W., Hu, L., Lee, T.K., Wo, J.Y., Ng, I.O., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132 (2007), 2542–2556.
11. [11] Yamashita, T., Honda, M., Nakamoto, Y., Baba, M., Nio, K., Hara, Y., et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 57 (2013), 1484–1497.
12. [12] Mima, K., Okabe, H., Ishimoto, T., Hayashi, H., Nakagawa, S., Kuroki, H., et al. CD44s regulates the TGF-beta-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 72 (2012), 3414–3423.
13. [13] Zhao, W., Wang, L., Han, H., Jin, K., Lin, N., Guo, T., et al. 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel alpha2delta1 subunit. Cancer Cell 23 (2013), 541–556.
14. [14] Rountree, C.B., Mishra, L., Willenbring, H., Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology 55 (2012), 298–306.
15. [15] Oishi, N., Yamashita, T., Kaneko, S., Molecular biology of liver cancer stem cells. Liver Cancer 3 (2014), 71–84.
16. [16] Tarlow, B.D., Pelz, C., Naugler, W.E., Wakefield, L., Wilson, E.M., Finegold, M.J., et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 15 (2014), 605–618.
17. [17] Quasdorff, M., Hosel, M., Odenthal, M., Zedler, U., Bohne, F., Gripon, P., et al. A concerted action of HNF4alpha and HNF1alpha links hepatitis B virus replication to hepatocyte differentiation. Cell Microbiol 10 (2008), 1478–1490.
18. [18] Wang, W.H., Studach, L.L., Andrisani, O.M., Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication. Hepatology 53 (2011), 1137–1147.
19. [19] Studach, L.L., Menne, S., Cairo, S., Buendia, M.A., Hullinger, R.L., Lefrancois, L., et al. Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein. Hepatology 56 (2012), 1240–1251.
20. [20] Margueron, R., Reinberg, D., The Polycomb complex PRC2 and its mark in life. Nature 469 (2011), 343–349.
21. [21] Thornton, S.R., Butty, V.L., Levine, S.S., Boyer, L.A., Polycomb Repressive Complex 2 regulates lineage fidelity during embryonic stem cell differentiation. PLoS One, 9, 2014, e110498.
22. [22] Terradillos, O., Billet, O., Renard, C.A., Levy, R., Molina, T., Briand, P., et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 14 (1997), 395–404.
23. [23] Madden, C.R., Finegold, M.J., Slagle, B.L., Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. J Virol 75 (2001), 3851–3858.
24. [24] Zhang, H., Diab, A., Fan, H., Mani, S.K., Hullinger, R., Merle, P., et al. PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus-Induced Liver Carcinogenesis. Cancer Res 75 (2015), 2363–2374.
25. [25] de Boer, C.J., van Krieken, J.H., Janssen-van Rhijn, C.M., Litvinov, S.V., Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 188 (1999), 201–206.
26. [26] Dolle, L., Theise, N.D., Schmelzer, E., Boulter, L., Gires, O., van Grunsven, L.A., EpCAM and the biology of hepatic stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol 308 (2015), G233–G250.
27. [27] Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk, M., et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11 (2009), 162–171.
28. [28] Cole, M.F., Johnstone, S.E., Newman, J.J., Kagey, M.H., Young, R.A., Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells. Genes Dev 22 (2008), 746–755.
29. [29] Marson, A., Foreman, R., Chevalier, B., Bilodeau, S., Kahn, M., Young, R.A., et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 3 (2008), 132–135.
30. [30] Pasini, D., Bracken, A.P., Hansen, J.B., Capillo, M., Helin, K., The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol 27 (2007), 3769–3779.
31. [31] Chamberlain, S.J., Yee, D., Magnuson, T., Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. Stem Cells 26 (2008), 1496–1505.
32. [32] Ladner, S.K., Otto, M.J., Barker, C.S., Zaifert, K., Wang, G.H., Guo, J.T., et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 41 (1997), 1715–1720.
33. [33] Ni, Y., Lempp, F.A., Mehrle, S., Nkongolo, S., Kaufman, C., Falth, M., et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146 (2014), 1070–1083.
34. [34] Pez, F., Lopez, A., Kim, M., Wands, J.R., Caron de Fromentel, C., Merle, P., Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol 59 (2013), 1107–1117.
35. [35] Bracken, A.P., Dietrich, N., Pasini, D., Hansen, K.H., Helin, K., Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20 (2006), 1123–1136.
36. [36] Seeger, C., Mason, W.S., Molecular biology of hepatitis B virus infection. Virology 479–480C (2015), 672–686.
37. [37] Tarn, C., Bilodeau, M.L., Hullinger, R.L., Andrisani, O.M., Differential immediate early gene expression in conditional hepatitis B virus pX-transforming versus nontransforming hepatocyte cell lines. J Biol Chem 274 (1999), 2327–2336.
38. [38] Wu, J.C., Merlino, G., Fausto, N., Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A 91 (1994), 674–678.
39. [39] Amaddeo, G., Cao, Q., Ladeiro, Y., Imbeaud, S., Nault, J.C., Jaoui, D., et al. Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut 64 (2015), 820–829.
40. [40] Kim, N.H., Kim, H.S., Kim, N.G., Lee, I., Choi, H.S., Li, X.Y., et al. P53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal, 4, 2011, ra71.
41. [41] Boyault, S., Rickman, D.S., de Reynies, A., Balabaud, C., Rebouissou, S., Jeannot, E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 (2007), 42–52.
42. [42] Li, T., Chen, H., Li, W., Cui, J., Wang, G., Hu, X., et al. Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines. Hum Mol Genet 23 (2014), 117–128.
43. [43] Sarma, K., Cifuentes-Rojas, C., Ergun, A., Del Rosario, A., Jeon, Y., White, F., et al. ATRX Directs Binding of PRC2 to Xist RNA and Polycomb Targets. Cell 159 (2014), 869–883.
44. [44] Lachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 18 (2012), 4997–5007.
45. [45] Huang, H.P., Chen, P.H., Yu, C.Y., Chuang, C.Y., Stone, L., Hsiao, W.C., et al. Epithelial cell adhesion molecule (EpCAM) complex proteins promote transcription factor-mediated pluripotency reprogramming. J Biol Chem 286 (2011), 33520–33532.
46. [46] Lin, C.W., Liao, M.Y., Lin, W.W., Wang, Y.P., Lu, T.Y., Wu, H.C., Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. J Biol Chem 287 (2012), 39449–39459.
47. [47] Yamashita, T., Budhu, A., Forgues, M., Wang, X.W., Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 67 (2007), 10831–10839.
48. [48] Yamashita, T., Forgues, M., Wang, W., Kim, J.W., Ye, Q., Jia, H., et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68 (2008), 1451–1461.
49. [49] De Jesus-Acosta, A., Laheru, D., Maitra, A., Arcaroli, J., Rudek, M.A., Dasari, A., et al. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs 32 (2014), 739–745.
50. [50] Richter, S., Bedard, P.L., Chen, E.X., Clarke, B.A., Tran, B., Hotte, S.J., et al. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drugs 32 (2014), 243–249.
51. [51] Le, P.N., McDermott, J.D., Jimeno, A., Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther 146 (2015), 1–11.